Mercado de neoantígenos: mapeo competitivo y perspectivas estratégicas para 2031

  • Report Code : TIPRE00021781
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 151
Buy Now

El mercado de neoantígenos fue valorado en US$ 2.71.428,57 mil en 2023, y se proyecta alcanzar US$ 10.54.783,54 mil en 2028; se espera que crezca a una tasa compuesta anual del 31,2 % entre 2023 y 2028.

Los neoantígenos son antígenos desarrollados recientemente que históricamente no han sido detectados por el sistema inmunológico. Las alteraciones en las proteínas tumorales pueden resultar en el desarrollo de neoantígenos causados por mutaciones o proteínas virales. Los neoantígenos se utilizan en tratamientos selectivos para células cancerosas.
El mercado de neoantígenos está segmentado según el tratamiento, la especialidad terapéutica y la geografía. Según la geografía, el mercado está segmentado en América del Norte, Europa, Asia Pacífico, Medio Oriente y Asia. África y América del Sur y Central. El informe ofrece información y un análisis en profundidad del mercado de neoantígenos haciendo hincapié en varios parámetros, como las tendencias del mercado, los avances tecnológicos, la dinámica del mercado y el análisis del panorama competitivo de los principales actores del mercado en todo el mundo. También incluye análisis de impacto de COVID-19 en todas las regiones. Se estima que es probable que el mercado tenga una tasa de crecimiento constante durante el período previsto.

regiones lucrativas para el mercado de neoantígenos

Perspectivas del mercado

Desarrollos en vacunas de neoantígenos contra Cáncer

Los avances en biotecnología han llevado a una mayor aceptación de la inmunoterapia, impulsando aún más su uso en medicamentos personalizados. La inmunoterapia se usa ampliamente para tratar el cáncer; Algunos procedimientos de inmunoterapia implican el uso de neoantígenos, los antígenos presentes en la superficie de las células cancerosas. Por tanto, se están estudiando ampliamente las aplicaciones de los neoantígenos para tratar el cáncer. La singularidad de los neoantígenos permite a los investigadores identificar las características de los pacientes. sistema inmunológico y encontrar antígenos para atacar las células cancerosas sin alterar las células sanas.
Los avances en inmunoterapia se aceleraron después de 2015, cuando se realizó el primer ensayo clínico de la vacuna de neoantígeno. En 2017, Neon Therapeutics publicó dos estudios de ensayos clínicos adicionales que demostraron la eficacia de la vacuna de neoantígeno para tratar el melanoma (cáncer de piel) en humanos. Los resultados positivos de los ensayos clínicos han atraído a varias empresas emergentes para descubrir y desarrollar terapias contra el cáncer basadas en neoantígenos. Muchas empresas han mostrado interés en el desarrollo de neoantígenos. A continuación se muestran algunos ejemplos de empresas involucradas en el desarrollo de neoantígenos.

  • BioNTech SE es una empresa alemana que opera en el mercado de vacunas de neoantígenos. BioNTech SE ha desarrollado una plataforma Mutanome de vacunas individualizadas contra el cáncer (IVAC) que diseña moléculas de ARN para producir una vacuna de neoantígeno personalizada. Los ensayos clínicos de IVAC dirigidos al cáncer de mama triple negativo, múltiples tipos de tumores y melanoma están pendientes.
  • La plataforma ATLAS de Genocea Biosciences utiliza un método ex-vivo para desarrollar neoantígenos vacunas. Genocea Biosciences ha recaudado ~91 millones de dólares en fondos de inversores como Polaris Partners, GlaxoSmithKline y Johnson & Johnson Innovation desarrollará su vacuna neoantígena contra el cáncer: GEN-009. Actualmente en el ensayo clínico de Fase 1a/2, la vacuna está diseñada para tratar el melanoma, el cáncer de pulmón y los carcinomas.
  • Gritstone Oncology utiliza su plataforma de inteligencia artificial, EDGE, para desarrollar vacunas neoantígenas utilizando un en -silico enfoque. La empresa ha desarrollado dos productos GRANITE-001 y SLATE-001. GRANITE-001 está diseñado como un tratamiento individual basado en el tipo de tumor específico del paciente, mientras que SLATE-001 está formulado como una vacuna de neoantígeno común que se puede usar en múltiples pacientes que muestran un neoantígeno similar.
  • Agenus Inc. ha desarrollado la vacuna neoantígena AutoSynVax (ASV) que se administra con un adyuvante estimulador QS-21 para tratar tumores sólidos. Actualmente, ASV se encuentra en el ensayo clínico de fase 1 en EE. UU.
  • Desde 2016, Moderna, Inc. participa en ensayos clínicos de su vacuna personalizada contra el cáncer (PCV) mRNA-4157 en combinación con Keytruda de Merck. En noviembre de 2020, Moderna, Inc. publicó actualizaciones sobre sus vacunas contra el cáncer indicando que la administración de mRNA-4157 en combinación con Keytruda es bien tolerada en todos los niveles de dosis y ha producido respuestas en los pacientes.

Tales Los avances en las vacunas de neoantígenos contra el cáncer están impulsando el crecimiento del mercado.

Información basada en el tratamiento

Según el tratamiento, el mercado de neoantígenos se segmenta en terapia combinada y monoterapia. En 2023, se estima que el segmento de terapia combinada tendrá una mayor participación de mercado. Sin embargo, se espera que el segmento de monoterapia tenga un crecimiento más rápido durante el período de pronóstico.

Mercado global de neoantígenos, por tratamiento: 2020 y 2020 2028

Información basada en la especialidad terapéutica

Basado en la especialidad terapéutica, el mercado de neoantígenos se segmenta en cáncer gastrointestinal, cáncer de pulmón, tumores sólidos y sistemas urinarios. cánceres, melanoma, cáncer de cabeza y cuello, y otros. En 2023, se estima que el segmento del cáncer gastrointestinal tendrá la mayor participación del mercado y se espera que crezca al ritmo más rápido en los próximos años.

Perspectivas estratégicas< /p>

Los actores del mercado adoptaron en gran medida estrategias inorgánicas para satisfacer la cambiante demanda de los clientes y mantener sus servicios mejorados. Por ejemplo, en enero de 2021, Genocea anuncia la publicación del descubrimiento del cáncer debido a los beneficios de la identificación de neoantígenos mediante la plataforma ATLAS. Este descubrimiento fortalece las inmunoterapias con neoantígenos al garantizar teóricamente que se dirijan a los neoantígenos correctos mientras eliminan los inhibidores.

Por tratamiento

  • Terapia combinada
  • Monoterapia

Por especialidad terapéutica

  • Cáncer gastrointestinal
  • Cáncer de pulmón
  • Sólido Tumores
  • Cánceres del sistema urinario
  • Melanoma
  • Cáncer de cabeza y cuello
  • Otros

Por Geografía

  • América del Norte
    • Estados Unidos
    • Canadá
    • México
  • Europa
    • Francia
    • Alemania
    • Italia
    • Reino Unido
    • España
    • Resto de Europa
  • Asia Pacífico (APAC)
    • China
    • India
    • Corea del Sur
    • < li>Japón
    • Australia
    • Resto de APAC
  • Medio Oriente y Asia África (MEA)
    • Sudáfrica
    • Arabia Saudita
    • EAU
    • Resto de MEA
  • América del Sur y Central (SCAM)
    • Brasil
    • Argentina
    • Resto de SCAM
  • Perfiles de la empresa

    • Achilles Therapeutics plc
    • Advaxis, Inc.
    • Frame Cancer Therapeutics
    • Genocea, Gradalis, Inc.
    • Gritstone Oncología
    • Immunicum AB
    • Medigene AG
    • Ziopharm Oncología, Inc.
    • Moderna, Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is are Neoantigens?

Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells.

What are the driving factors for the neoantigens market across the globe?

Key factors that are driving growth of the market are developments in neoantigen vaccines against cancer and increasing prevalence of cancer. However, possible side effects associated with neoantigen vaccines are likely to hinder the growth of the neoantigens market.

How many neoantigens are commercialized?

Several companies into clinical trial phases for their respective neoantigens. It is expected that by 2023, companies will commercialize their products in the market. In addition, it is expected that the cost of neoantigens will be much higher than cancer vaccines.

The List of Companies - Neoantigens Market

  1. Achilles Therapeutics plc
  2. Advaxis, Inc.
  3. Frame Cancer Therapeutics
  4. Genocea
  5. Gradalis, Inc.
  6. Gritstone Oncology
  7. Immunicum AB
  8. Medigene AG
  9. Ziopharm Oncology, Inc.
  10. Moderna, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports